Highlights

  • Vitura Health (ASX:VIT) traded at AUD 0.027, down 12.90% during the morning Trading session on 26 August 2026.
  • FY26 Revenue increased 5.7% to $131.2m, supported by growth across sales, distribution and clinics.
  • Canview sales increased 17% to 1.13 million medicinal cannabis and nicotine vaping products.
  • Doctors on Demand revenue increased 13%, with consultation numbers exceeding 420,000.
  • The company implemented Leadership and cost structure changes targeting improved FY27 performance.

Vitura Health Limited (ASX:VIT) has reported its FY26 financial results, highlighting revenue growth across its digital health operations while outlining a strategic reset focused on improving Earnings quality and long-term profitability.

The company traded at AUD 0.027, down 12.90% during the morning trading session on 26 August 2026. Over the past year, Vitura Health’s share price has declined 61.43%.

The digital health company recorded higher revenue during FY26, supported by growth in product distribution, medicinal cannabis volumes and telehealth activity. However, profitability was affected by increased competition, pricing pressure and internal organisational changes.

Financial Performance

Vitura reported total revenue of $131.2m for FY26, increasing 5.7% from $124.0m in FY25.

Sales and distribution revenue increased to $100.4m, up 4.2%, while clinics and services revenue rose 11.3% to $30.8m.

Despite revenue growth, profitability was impacted by Margin compression across the industry, driven by increased competition and price discounting.

Normalised EBITDA declined to $3.0m from $8.9m in FY25, while normalised NPAT decreased to $0.1m from $3.9m.

The company reported a statutory net loss after tax of $4.4m, compared with a $3.1m profit in FY25.

Vitura said the decline reflected pressure on margins, along with the impact of operational changes and one-off costs.

Product Distribution Growth

Vitura continued expanding activity across its Canview platform during FY26.

Burleigh Heads Cannabis sold 1.13 million medicinal cannabis and nicotine vaping products through Canview, representing a 17% increase compared with the prior corresponding period.

The company currently distributes products to four out of every five pharmacies actively supplying medicinal cannabis in Australia.

Nicotine vaping product revenue more than doubled during FY26 to $11.5m.

Vitura said the broader medicinal cannabis market experienced increased competition, greater product availability and pricing pressure during the year, affecting margins across the Supply chain.

The company has focused on improving supplier relationships, refining product mix and balancing Volume growth with profitability.

Clinic Expansion

Vitura’s specialty clinics division continued expanding through its telehealth platforms.

Doctors on Demand recorded 13% revenue growth during FY26, with total consultation numbers increasing 11% to more than 420,000 consultations.

The integration of Candor Medical continued during the year, adding access to approximately 15,000 active patients through its digital platform.

Both CDA Clinics and Cannadoc have been migrated onto the same platform, supporting a more consistent patient experience and operational efficiency.

Vitura said Doctors on Demand is positioned to support demand for digital healthcare access, including general medical consultations, urgent care and specialist referrals.

Leadership Transition

FY26 represented a period of internal transition for Vitura, with leadership and organisational changes implemented to better align the Business with its current scale and strategic priorities.

Justin James commenced as Chief Executive Officer on 1 June 2026.

The company has also appointed James Frayne as Chief Financial Officer, with his commencement scheduled for 1 October 2026, while Trudy Adams commenced as Executive General Manager Strategy & Technology and Risk in August 2026.

Vitura said the leadership changes are designed to transition the company from a start-up mindset towards a more mature operating model focused on governance, financial discipline and sustainable value creation.

Cost Management

Following the leadership transition, Vitura introduced a leaner leadership structure in July 2026.

The changes are expected to deliver approximately $1m in annualised savings.

The company said these measures are already contributing to improvements in efficiency and are supporting its FY27 outlook.

Vitura has also commenced a broader strategic business review focused on improving earnings quality, strengthening execution and applying greater discipline to Capital allocation.

Future Opportunities

Vitura continues to focus on opportunities across medicinal cannabis, nicotine vaping products and specialty pharmaceuticals.

The company identified medicinal vaping products for smoking cessation as an emerging growth area during FY26.

It is also progressing opportunities in specialty pharmaceutical areas, including MDMA and psilocybin-assisted treatments for mental health through its broader platform.

These initiatives are being evaluated under a more disciplined capital framework focused on long-term sustainable value.

FY27 Outlook

Vitura’s priority for FY27 is returning to sustainable, profitable growth.

The company expects revenue growth to moderate as lower-margin activities are rationalised, with the objective of improving EBITDA performance.

Key areas of focus include strengthening the Canview platform, improving supplier partnerships, expanding medicinal vape opportunities and progressing specialty pharmaceutical initiatives.

CEO Justin James said the changes implemented during late FY26 and early FY27 have established a stronger foundation for future performance.

Investor Takeaway

Vitura Health’s FY26 results reflect a year of revenue growth but also highlight challenges from market competition, pricing pressure and organisational transition. The company has responded through leadership changes, cost reductions and a renewed focus on earnings quality. Investors may continue watching the impact of the operating reset, margin improvement initiatives and progress towards sustainable profitability in FY27.